The exciting potential of 2020, as seen in January last year with the launch of the European Green Deal (EGD) and the EU’s energy transition towards being carbon neutral by 2050, was brutally and painfully destroyed by COVID-19. There is simply no way of avoiding that truth as we seek to make sense of what now lies ahead for Europe in 2021.
As we embark on what now amounts to a relaunch of both personal and business objectives, however, the challenge is to move Europe’s bioenergy forward. That will include taking advantage of fresh funding streams and sector opportunities, some of which have ironically emerged from the wreckage of COVID-19.
Delaying COP26 until November this year, for example, may well prove to be a bonus for those who support the development of renewable sources of energy. Similarly, the EU’s €672.5 billion COVID-19 Recovery and Resilience Facility (RRF), promises to provide an injection of funding into the bioenergy sector which we could only have been dreamed of in more normal times.